Abstract | BACKGROUND: METHOD: From inception to May 4, 2022, manual searches were conducted to identify all eligible literature using the PubMed database for the published phase III clinical trial and a randomize-controlled trial testing the role of adjuvant chemoradiotherapy in operable gastric cancer. RESULTS: Two trials with a total of 1004 patients were selected as a result. Adjuvant CRT was found to have no effect on disease-free survival (DFS) in gastric cancer patients treated with D2 surgery (HR: 0.70 (0.62-1.02), p: 0.07). However, patients with intestinal-type gastric cancers exhibited significantly longer DFS (HR: 0.58 (0.37-0.92), p = 0.02). DISCUSSION:
|
Authors | Hasan Cagri Yildirim, Deniz Can Guven, Arif Akyildiz, Suayib Yalcin, Omer Dizdar |
Journal | Irish journal of medical science
(Ir J Med Sci)
Vol. 192
Issue 6
Pg. 2631-2634
(Dec 2023)
ISSN: 1863-4362 [Electronic] Ireland |
PMID | 36867373
(Publication Type: Meta-Analysis, Journal Article)
|
Copyright | © 2023. The Author(s), under exclusive licence to Royal Academy of Medicine in Ireland. |
Topics |
- Humans
- Stomach Neoplasms
(therapy, pathology)
- Chemoradiotherapy, Adjuvant
(adverse effects)
- Disease-Free Survival
- Chemotherapy, Adjuvant
- Lymph Node Excision
- Chemoradiotherapy
|